Interview with Selwyn Kahanovitz, CEO, Litha Healthcare Group Limited
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
Address: No 106, 16th Road, Midrand, 1686, Gauteng, South Africa
Tel: +27 11 516 1700
Web: http://www.lithahealthcare.co.za/
Litha Healthcare Group Limited is the result of the successful acquisition by Myriad Medical Holdings of Litha Healthcare Holdings (Proprietary) Limited in 2010.
Litha is a diversified healthcare company, with headquarters in Johannesburg, South Africa. Established in 1992 and with over 340 employees nationally, we are the only truly diversified Healthcare group listed on the Johannesburg Stock Exchange.
Litha Healthcare Group is divided into three Divisions;
Litha Biotech
Litha Medical
Litha Pharma
Within each Division there are 100% owned business units with the exception of The Biovac Institute which is a Public Private Partnership (PPP) between the SA Government and The Biovac Consortium.
Each Division is lead by a Divisional CEO. Litha Healthcare Group Limited provides healthcare solutions to hospitals, clinics, specialists pharmacies and general and allied practitioners either through distribution networks or directly.
The group’s diversified businesses include the following areas of healthcare:
Biotechnology : Vaccines
Medical devices : Consumables and Equipment
Pharmaceuticals : Generic, Ethical and Complimentary
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
Building on the recent controversy over Tanzania’s handling of a suspected Marburg virus outbreak, Medicines for Africa’s Lenias Hwenda explores how African nations often face disproportionate consequences for outbreak transparency—penalties…
John M. Mwangi of Bayer Pharmaceuticals, writing in the December 2024 edition of DIA’s Global Forum magazine, examines why longstanding calls to implant more of the pharmaceutical manufacturing chain into…
The IFPMA’s Sarah Adam, writing in the July 2024 edition of DIA’s Global Forum magazine, looks back on an insightful discussion on the progress towards an African Medicines Agency at…
Several major scientific breakthroughs in HIV prevention and treatment in the past 40 years have successfully transformed HIV from a near-certain ‘death sentence’ to a manageable chronic disease where many…
In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step…
A leading voice in the global fight against HIV, Professor Linda-Gail Bekker works across both scientific research and activism. As CEO and founder of the Desmond Tutu Health Foundation, Prof…
Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to…
Medicines for Africa’s Lenias Hwenda argues that the success of the much-talked-about African Medicines Agency hinges on a critical mass of African national regulators achieving WHO Level 3 maturity status.…
Writing in the February 2024 edition of the DIA Global Forum magazine, Verena Pfaffinger and Ilona Baraniak-Lang of PharmaLex examine how the drug shortages seen in the global south during…
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
See our Cookie Privacy Policy Here
